Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

NCT06598631 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.

Conditions

Interventions

Sponsor

Eli Lilly and Company